N., Vasas, S., Tsamandouras, N., & Birnbaum, M
My view has not changed: BPC-157 lacks adequate human evidence for ulcerative colitis, Crohn's disease or "gut healing", and it should not replace established IBD treatment
Interestingly, the discovery of poly-agonist drugs that activate multiple gutbrain pathways promises to further transform the management of metabolic diseases besides type 2 diabetes, including obesity and non-alcoholic fatty liver disease (NAFLD) [6,7,8]
What Else Does Retatrutide Do
No, GLP-1 receptor agonists are not licensed by the MHRA or recommended by NICE for ADHD treatment